Bazedoxifene, an FDA-approved selective estrogen receptor modulator (SERM) with conjugated estrogens, was previously identified to reduce breast cancer cell proliferation and downregulate ERα and cyclin D1; however, its antitumor mechanism was not elucidated until recently (211). This evidence concerns the gene ESR1 and breast carcinoma.